跳至主要内容
临床试验/EUCTR2016-001193-15-DK
EUCTR2016-001193-15-DK进行中(未招募)1 期

Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II trial from the Danish renal cancer group (DARENCA study-4). - Folic Acid Supplement for Treating adverse Events in metastatic Renal Cell Carcinoma (FASTERCC).

Department of Oncology, Aarhus University Hospital0 个研究点目标入组 100 人开始时间: 2016年5月18日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Patients displaying CTCAE =2 mucositis during TKI or mTOR inhibitor treatment.
  • 2.Signed written informed consent obtained prior to any study specific procedures.
  • 3.Patient must be willing and able to comply with the protocol.
  • 4.Age > 18.
  • 5.Biopsy proven locally advanced or metastatic renal cell carcinoma.
  • 6.Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.
  • 7.Fertile women of childbearing potential (<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).
  • 8.Karnofsky Performance status > 60%.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 50
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • Known hypersensitivity to folic acid

研究者

发起方
Department of Oncology, Aarhus University Hospital

相似试验